|
gptkbp:instanceOf
|
gptkb:antiretroviral_therapy
gptkb:protease_inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AE10
|
|
gptkbp:bioavailability
|
37% (with ritonavir)
|
|
gptkbp:brand
|
gptkb:Prezista
|
|
gptkbp:CASNumber
|
206361-99-1
|
|
gptkbp:category
|
gptkb:antiviral_drug
HIV/AIDS drug
|
|
gptkbp:combines
|
gptkb:cobicistat
gptkb:ritonavir
|
|
gptkbp:contraindication
|
severe liver impairment
|
|
gptkbp:developedBy
|
gptkb:Tibotec
|
|
gptkbp:eliminationHalfLife
|
15 hours
|
|
gptkbp:hasMolecularFormula
|
C27H37N3O7S
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 protease
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
rash
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:J05AE
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Darunavir
|